Vaccinex’s mission is to deliver innovative therapies that improve the lives of patients and provide treatment solutions for critical unmet needs. Through deep understanding of science and pathology of disease, we are pioneering a differentiated approach to treating neurologic diseases and cancer with novel antibody therapeutics. We are grateful to the patients, families, and the clinical staff that participate in our clinical trials. Each individual’s participation contributes to the potential to realize benefit for patients today and to advance our understanding of disease for the next generation.
 

Physicians & Researchers

Vaccinex seeks to build clinical programs that beneficially impact patient care. With that goal in mind, we are developing a pipeline of novel candidate therapeutics that we hope will improve upon existing therapies and offer patient treatment options that improve their quality of life.

Product Pipeline

Click to download

 

Clinical Trials with pepinemab

Neurological Disease

Click for more information about Neurology

Recruiting
NCT04381468

SIGNAL-AD Alzheimer’s Disease
Evaluating the Safety and Efficacy of our drug Pepinemab in Patients with Alzheimer’s Disease.
Phase 1b/2

Condition(s) Alzheimer Disease (AD)

SPONSOR

COLLABORATORS
Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation

Completed
NCT02481674

SIGNAL Huntington's Disease
Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of our drug Pepinemab in Patients with Late Prodromal and Early Manifest Huntington Disease.
Phase 2

Condition(s) Huntington's Disease

SPONSOR

 

Oncology – Solid Tumors

Click for more information about Immuno-Oncology

Recruiting
NCT04815720

Keynote B84 Head and Neck Cancer
Evaluating the Safety and Efficacy of our Drug Pepinemab in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Phase 1b/2

Condition(s) Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

SPONSOR

COLLABORATOR
Merck Sharp & Dohme Corp.

Completed
NCT03268057

CLASSICAL – Lung Cancer
Evaluating the Safety and Efficacy of our Drug Pepinemab in Combination with Avelumab in Patients with Advanced Non-Small Cell Lung Cancer.
Phase 1b/2

Condition(s) Carcinoma, Non-Small-Cell Lung

SPONSOR

COLLABORATOR
Merck KGaA, Darmstadt, Germany

Link to manuscript

 

Other Immunotherapy Trials with pepinemab

Recruiting
NCT05378464

Adoptive Cell Therapy trial – Breast Cancer
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Phase 1

Condition(s) Metastatic Breast Cancer

SPONSOR
H. Lee Moffitt Cancer Center and Research Institute

COLLABORATOR
Vaccinex

Recruiting
NCT03690986

Integrated Biomarker Trial – Head and Neck Cancer
Integrated Biomarker Trial of Pepinemab in Combination with Ipilimumab or Nivolumab in Patients with Head and Neck Cancer.
Phase 1

Condition(s) Squamous Cell Carcinoma of the Head and Neck

SPONSOR
Emory University

COLLABORATOR
Vaccinex

Recruiting
NCT03769155

Integrated Biomarker Trial – Melanoma
Integrated Biomarker Trial of Pepinemab with or without Ipilimumab and/or Nivolumab in Patients with Resectable Stage IIIB-D Melanoma.
Phase 1

Condition(s) Cutaneous Melanoma

SPONSOR
Emory University

COLLABORATOR
Bristol Myers Squibb
Vaccinex

Active, not recruiting
NCT03320330

Treating Younger Patients with Recurrent, Relapsed or Refractory Solid Tumors
Pepinemab, a Humanized Monoclonal Antibody to Semaphorin 4D, in Pediatric Patients with Relapsed or Refractory Solid Tumors.
Phase 1/2

Condition(s) Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma

SPONSOR
Children's Oncology Group

COLLABORATOR
National Cancer Institute (NCI)
Vaccinex